2016;5(2):e002343
Gut dysbiosis has been associated with higher concentrations of these hormones, which might inhibit hormone signaling and alter energy metabolism ( N Engl J Med , 2024)
Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
Tirzepatide is the current evidence leader
Innovation in Oral Obesity Drug Design: Analyses the transition from conventional weight loss medicines to innovative oral GLP-1 agonists, dual incretin agonists, triple agonists, amylin and small molecule obesity drug classes
Menopausal women may particularly benefit from the metabolic effects that help offset menopause-related metabolic slowdown